Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

KUZELOVA Katerina BRODSKA Barbora SCHETELIG Johannes ROLLING Christoph RÁČIL Zdeněk WALZ Juliane Stickel HELBIG Grzegorz FUCHS Ota VRANA Milena PECHERKOVA Pavla SALEK Cyril MAYER Jiří

Year of publication 2018
Type Article in Periodical
Magazine / Source Plos one
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1371/journal.pone.0204290
Keywords Acute myeloid leukemia
Description Acute myeloid leukemia with mutated nucleophosmin (NPMc+AML) forms a distinct AML subgroup with better prognosis which can potentially be associated with immune response against the mutated nucleophosmin (NPM). As the T-cell-mediated immunity involves antigen presentation on HLA class I molecules, we hypothesized that individuals with suitable HLA type could be less prone to develop NPMc+AML. We compared HLA class I distribution in NPMc+AML patient cohort (398 patients from 5 centers) with the HLA allele frequencies of the healthy population and found HLA-A*02, B*07, B*40 and C*07 underrepresented in the NPMc+AML group. Presence of B*07 or C*07:01 antigen was associated with better survival in patients without concomitant FLT3 internal tandem duplication. Candidate NPM-derived immunopeptides were found for B*40 and B*07 using prediction software tools. Our findings suggest that a T-cell-mediated immune response could actually explain better prognosis of NPMc+ patients and provide a rationale for attempts to explore the importance of immunosuppressive mechanisms in this AML subgroup.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info